190 related articles for article (PubMed ID: 21080955)
1. Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors.
Blish KR; Clausen KA; Hawkins GA; Garvin AJ; Willingham MC; Turner JC; Torti FM; Torti SV
J Exp Clin Cancer Res; 2010 Nov; 29(1):147. PubMed ID: 21080955
[TBL] [Abstract][Full Text] [Related]
2. Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor.
Ohshima J; Haruta M; Arai Y; Kasai F; Fujiwara Y; Ariga T; Okita H; Fukuzawa M; Hata J; Horie H; Kaneko Y
Genes Chromosomes Cancer; 2009 Dec; 48(12):1037-50. PubMed ID: 19760604
[TBL] [Abstract][Full Text] [Related]
3. A human bone morphogenetic protein antagonist is down-regulated in renal cancer.
Blish KR; Wang W; Willingham MC; Du W; Birse CE; Krishnan SR; Brown JC; Hawkins GA; Garvin AJ; D'Agostino RB; Torti FM; Torti SV
Mol Biol Cell; 2008 Feb; 19(2):457-64. PubMed ID: 18032587
[TBL] [Abstract][Full Text] [Related]
4. Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.
Safford SD; Goyeau D; Freemerman AJ; Bentley R; Everett ML; Grundy PE; Skinner MA
Ann Surg Oncol; 2003 Mar; 10(2):136-43. PubMed ID: 12620908
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity at 7p in Wilms' tumour development.
Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
[TBL] [Abstract][Full Text] [Related]
7. SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer.
Clausen KA; Blish KR; Birse CE; Triplette MA; Kute TE; Russell GB; D'Agostino RB; Miller LD; Torti FM; Torti SV
Breast Cancer Res Treat; 2011 Oct; 129(3):737-46. PubMed ID: 21113658
[TBL] [Abstract][Full Text] [Related]
8. Beta-catenin expression and mutation in adult and pediatric Wilms' tumors.
Su MC; Huang WC; Lien HC
APMIS; 2008 Sep; 116(9):771-8. PubMed ID: 19024596
[TBL] [Abstract][Full Text] [Related]
9. The parathyroid hormone-responsive B1 gene is interrupted by a t(1;7)(q42;p15) breakpoint associated with Wilms' tumour.
Vernon EG; Malik K; Reynolds P; Powlesland R; Dallosso AR; Jackson S; Henthorn K; Green ED; Brown KW
Oncogene; 2003 Mar; 22(9):1371-80. PubMed ID: 12618763
[TBL] [Abstract][Full Text] [Related]
10. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
11. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
12. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
13. Cancer. Converging on beta-catenin in Wilms tumor.
Nusse R
Science; 2007 May; 316(5827):988-9. PubMed ID: 17510350
[No Abstract] [Full Text] [Related]
14. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity at 2q37 in sporadic Wilms' tumor: putative role for miR-562.
Drake KM; Ruteshouser EC; Natrajan R; Harbor P; Wegert J; Gessler M; Pritchard-Jones K; Grundy P; Dome J; Huff V; Jones C; Aldred MA
Clin Cancer Res; 2009 Oct; 15(19):5985-92. PubMed ID: 19789318
[TBL] [Abstract][Full Text] [Related]
16. Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours.
Natrajan R; Warren W; Messahel B; Reis-Filho JS; Brundler MA; Dome JS; Grundy PE; Vujanic G; Pritchard-Jones K; Jones C
J Clin Pathol; 2008 Jan; 61(1):95-102. PubMed ID: 17369505
[TBL] [Abstract][Full Text] [Related]
17. Wnt signaling pathway analysis in renal cell carcinoma in young patients.
Bruder E; Moch H; Ehrlich D; Leuschner I; Harms D; Argani P; Briner J; Graf N; Selle B; Rufle A; Paulussen M; Koesters R
Mod Pathol; 2007 Dec; 20(12):1217-29. PubMed ID: 17873895
[TBL] [Abstract][Full Text] [Related]
18. 16q loss of heterozygosity and microsatellite instability in Wilms' tumor.
Mason JE; Goodfellow PJ; Grundy PE; Skinner MA
J Pediatr Surg; 2000 Jun; 35(6):891-6; discussion 896-7. PubMed ID: 10873032
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors.
Wirths O; Waha A; Weggen S; Schirmacher P; Kühne T; Goodyer CG; Albrecht S; Von Schweinitz D; Pietsch T
Lab Invest; 2003 Mar; 83(3):429-34. PubMed ID: 12649343
[TBL] [Abstract][Full Text] [Related]
20. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
